Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Picovir “not approvable” letter

Executive Summary

ViroPharma expects to receive a "not approvable" letter for cold treatment Picovir by May 31. Results of Phase I studies of the picornavirus treatment's interaction with oral contraceptives and the duration of the related CYP3A enzyme induction are expected this summer. ViroPharma and marketing partner Aventis "will work together to determine what further action will be taken with Picovir," ViroPharma says. FDA's Antiviral Drugs Advisory Committee voted not to recommend the product for approval March 19 (1"The Pink Sheet" March 25, p. 31)...

You may also be interested in...

Viropharma Picovir Oral Contraceptive Study Data Expected This Summer

Viropharma expects to have data from a Phase I drug interaction study of oral contraceptives and Picovir (pleconaril) in two to four months

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 

ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors

HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts